CHK1 inhibitors have gained attention as a potential treatment for small-cell lung cancer (SCLC) due to their ability to disrupt the DNA damage response (DDR) and enhance tumor sensitivity to chemotherapy. This evidence concerns the gene CHEK1 and small cell lung carcinoma.